Pharm-Olam Selected to Join BARDA’s Clinical Studies Network

October 8, 2020

Under the contract, Pharm-Olam will offer routine and response clinical services for the development of medical countermeasures.

Pharm-Olam, a clinical research organization, announced on Oct. 8, 2020 that it has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to join its Clinical Studies Network.

Under the contract, Pharm-Olam will offer routine and response clinical services for the development of medical countermeasures, a company press release said. The contract will last a minimum of two years with a maximum of five years and will be worth $250 million.

"We are pleased to have been selected by BARDA to support medical countermeasure development and the fight against emerging infectious diseases," said Jason Ezzelle, Pharm-Olam's chief commercial and government contracts officer, in the press release. "This agreement is the result of our focused investment in our infectious disease business, and further builds upon our growing federally-funded clinical trials portfolio, including support for Operation Warp Speed."

Source: Pharm-Olam